We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic, Inc. (HOLX - Free Report) reported second-quarter fiscal 2020 adjusted earnings per share (EPS) of 57 cents, down 1.7% year over year. The bottom line however surpassed the Zacks Consensus Estimate by 5.6%.
On a GAAP basis, the company’s earnings of 36 cents per share reflect an improvement from the year-ago quarter’s loss of $1.01 per share.
Revenues in Detail
Revenues grossed $756.1 million in the reported quarter, down 7.6% year over year (down 7.1% at constant exchange rate or CER) due to the divestiture of Cynosure. The metric was in line with the Zacks Consensus Estimate.
Excluding the divested Blood Screening and Medical Aesthetics businesses, total revenues were $740.9 million, up 1.3% year over year and 1.9% at CER. Organic revenues (excluding divestitures and the acquired SuperSonic Imagine or SSI business) of $735.1 million increased 0.5% and 1.1% at CER.
U.S. revenues of $574.9 million fell 6.6%. Additionally, international revenues of $181.2 million declined 10.7% or 8.6% at CER.
Organically, revenues in the United States fell 1% year over year to $558.5 million in the quarter. However, international revenues were up 6% (up 8.4% at CER) to $176.6 million.
Segments in Detail
Revenues at the Diagnostics segment rose 7.6% year over year (up 8.3% at CER) to $319.2 million in the quarter under review, with Molecular Diagnostics being the major driver. Molecular Diagnostics’ revenues of $190.6 million climbed 13.6% (up 14.2% at CER), continuing the division’s strong performance. Moreover, Blood Screening revenues of $15.2 million rose 13.5% (up 13.5% at CER).
Revenues at the Breast Health segment declined 4.3% (down 3.7% at CER) to $307.8 million. This is in line with the company’s preliminary results released earlier this month, where it had stated that weaker-than-expected sales of Breast Health products due to changing customer responses amid the COVID-19 outbreak would impact the segment’s revenues. Domestic sales were dismal in this segment in the quarter, with a 7.3% revenue decline year over year. However, outside the United States, Breast Health sales increased 7.2% in total and grew 0.6% (without SSI).
Revenues at the GYN Surgical business grew 3.1% (up 3.6% at CER) to $105.4 million, while revenues at Skeletal Health fell 2.1% (down 1.6% at CER) to $23.7 million.
Notably, the Medical Aesthetics segment no longer reports after the divestiture of Cynosure medical aesthetics business on Dec 30, 2019.
Operational Update
In the fiscal second quarter, Hologic’s adjusted gross margin remained flat year over year. According to the company, the benefits from the Cynosure Medical Aesthetics divestiture were offset by lower sales due to the pandemic, unfavorable product sales mix and a strong U.S. dollar.
Adjusted operating expenses amounted to $222.5 million, down 18.4% year over year. However, adjusted operating margin expanded 380 basis points to 31.5%.
Financial Update
Hologic exited the second quarter of fiscal 2020 with cash and cash equivalents of $799.8 million compared with $370.8 million at the end of first-quarter fiscal 2020. Total long-term debt was $3.56 billion at the end of the quarter under review, compared with $3.07 billion at the end of first-quarter fiscal 2020. The company completed the $205 million Accelerated Share Repurchase agreement announced in the first quarter and repurchased an additional 5.9 million shares of stock for $267.6 million before suspending its buy-back activities in March.
At the end of the fiscal second quarter, net cash provided by operating activities was $231.6 million compared with $238.1 million a year ago.
Guidance
Hologic expects significant adverse impact of the coronavirus pandemic on its revenues and operating income going forward. The company is currently unable to ascertain the scope and duration of the pandemic as well as quantify the actual impact. Accordingly, it has withdrawn its financial guidance for the second quarter and full-year 2020.
Our Take
Hologic’s top-line growth was led by a year-over-year rise in core GYN Surgical and Molecular Diagnostics sales. Earlier, the company had stated that its sales of GYN Surgical and Diagnostics products were adversely impacted by the deferral of elective procedures and physician office visits due to the coronavirus pandemic. Despite these adversities, these two segments registered growth in the quarter under review.
We are upbeat about the solid uptick in the company’s Diagnostics business resulting from robust sales of Panther Fusion SARS-CoV-2 assay after it received Emergency Use Authorization from the FDA. The company’s efforts to combat the pandemic by means of launch of assays on its Panther instrument and Panther Fusion platform buoy optimism.
On the flip side, the fall in its Breast Health revenues due to the pandemic is worrying.
Zacks Rank and Stocks to Consider
Hologic currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Aphria Inc. , Biogen Inc. (BIIB - Free Report) and Eli Lilly and Company (LLY - Free Report) .
Aphria reported third-quarter fiscal 2020 adjusted EPS of 2 cents, comparing favourably with the Zacks Consensus Estimate of a loss of 4 cents. Its net revenues of $64.4 million outpaced the consensus estimate by 14.6%. The company carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biogen currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Its revenues of $3.53 billion outpaced the consensus mark by 3.2%.
Eli Lilly delivered first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Its first-quarter revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company currently sports a Zacks Rank #1.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View
Hologic, Inc. (HOLX - Free Report) reported second-quarter fiscal 2020 adjusted earnings per share (EPS) of 57 cents, down 1.7% year over year. The bottom line however surpassed the Zacks Consensus Estimate by 5.6%.
On a GAAP basis, the company’s earnings of 36 cents per share reflect an improvement from the year-ago quarter’s loss of $1.01 per share.
Revenues in Detail
Revenues grossed $756.1 million in the reported quarter, down 7.6% year over year (down 7.1% at constant exchange rate or CER) due to the divestiture of Cynosure. The metric was in line with the Zacks Consensus Estimate.
Excluding the divested Blood Screening and Medical Aesthetics businesses, total revenues were $740.9 million, up 1.3% year over year and 1.9% at CER. Organic revenues (excluding divestitures and the acquired SuperSonic Imagine or SSI business) of $735.1 million increased 0.5% and 1.1% at CER.
Hologic, Inc. Price, Consensus and EPS Surprise
Hologic, Inc. price-consensus-eps-surprise-chart | Hologic, Inc. Quote
U.S. revenues of $574.9 million fell 6.6%. Additionally, international revenues of $181.2 million declined 10.7% or 8.6% at CER.
Organically, revenues in the United States fell 1% year over year to $558.5 million in the quarter. However, international revenues were up 6% (up 8.4% at CER) to $176.6 million.
Segments in Detail
Revenues at the Diagnostics segment rose 7.6% year over year (up 8.3% at CER) to $319.2 million in the quarter under review, with Molecular Diagnostics being the major driver. Molecular Diagnostics’ revenues of $190.6 million climbed 13.6% (up 14.2% at CER), continuing the division’s strong performance. Moreover, Blood Screening revenues of $15.2 million rose 13.5% (up 13.5% at CER).
Revenues at the Breast Health segment declined 4.3% (down 3.7% at CER) to $307.8 million. This is in line with the company’s preliminary results released earlier this month, where it had stated that weaker-than-expected sales of Breast Health products due to changing customer responses amid the COVID-19 outbreak would impact the segment’s revenues. Domestic sales were dismal in this segment in the quarter, with a 7.3% revenue decline year over year. However, outside the United States, Breast Health sales increased 7.2% in total and grew 0.6% (without SSI).
Revenues at the GYN Surgical business grew 3.1% (up 3.6% at CER) to $105.4 million, while revenues at Skeletal Health fell 2.1% (down 1.6% at CER) to $23.7 million.
Notably, the Medical Aesthetics segment no longer reports after the divestiture of Cynosure medical aesthetics business on Dec 30, 2019.
Operational Update
In the fiscal second quarter, Hologic’s adjusted gross margin remained flat year over year. According to the company, the benefits from the Cynosure Medical Aesthetics divestiture were offset by lower sales due to the pandemic, unfavorable product sales mix and a strong U.S. dollar.
Adjusted operating expenses amounted to $222.5 million, down 18.4% year over year. However, adjusted operating margin expanded 380 basis points to 31.5%.
Financial Update
Hologic exited the second quarter of fiscal 2020 with cash and cash equivalents of $799.8 million compared with $370.8 million at the end of first-quarter fiscal 2020. Total long-term debt was $3.56 billion at the end of the quarter under review, compared with $3.07 billion at the end of first-quarter fiscal 2020. The company completed the $205 million Accelerated Share Repurchase agreement announced in the first quarter and repurchased an additional 5.9 million shares of stock for $267.6 million before suspending its buy-back activities in March.
At the end of the fiscal second quarter, net cash provided by operating activities was $231.6 million compared with $238.1 million a year ago.
Guidance
Hologic expects significant adverse impact of the coronavirus pandemic on its revenues and operating income going forward. The company is currently unable to ascertain the scope and duration of the pandemic as well as quantify the actual impact. Accordingly, it has withdrawn its financial guidance for the second quarter and full-year 2020.
Our Take
Hologic’s top-line growth was led by a year-over-year rise in core GYN Surgical and Molecular Diagnostics sales. Earlier, the company had stated that its sales of GYN Surgical and Diagnostics products were adversely impacted by the deferral of elective procedures and physician office visits due to the coronavirus pandemic. Despite these adversities, these two segments registered growth in the quarter under review.
We are upbeat about the solid uptick in the company’s Diagnostics business resulting from robust sales of Panther Fusion SARS-CoV-2 assay after it received Emergency Use Authorization from the FDA. The company’s efforts to combat the pandemic by means of launch of assays on its Panther instrument and Panther Fusion platform buoy optimism.
On the flip side, the fall in its Breast Health revenues due to the pandemic is worrying.
Zacks Rank and Stocks to Consider
Hologic currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Aphria Inc. , Biogen Inc. (BIIB - Free Report) and Eli Lilly and Company (LLY - Free Report) .
Aphria reported third-quarter fiscal 2020 adjusted EPS of 2 cents, comparing favourably with the Zacks Consensus Estimate of a loss of 4 cents. Its net revenues of $64.4 million outpaced the consensus estimate by 14.6%. The company carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biogen currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Its revenues of $3.53 billion outpaced the consensus mark by 3.2%.
Eli Lilly delivered first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Its first-quarter revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company currently sports a Zacks Rank #1.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>